Kalmaro

Researchers are evaluating the effect of adding clindamycin to the usual treatment of skin and soft tissue infections caused by Staphylococcus aureus in patients from Sierra Leone. The study aims to see if this combination leads to faster healing and fewer infection recurrences. These infections can be severe due to toxins produced by the bacteria, and clindamycin is believed to reduce these toxins. The trial compares standard treatment, usually involving anti-staphylococcal penicillin with or without surgery to drain infection, to the same treatment plus clindamycin. Clindamycin is given either orally or intravenously for 7 days, with dosing adjusted by weight. Participants receive either the standard care alone or the standard care plus clindamycin, and the study is open-label, meaning both patients and doctors know which treatment is given. Participants will be adults with confirmed Staphylococcus aureus skin infections who require systemic therapy. They will be monitored for clinical cure at 7 and 14 days, changes in inflammation, symptom resolution time, possible side effects, microbiological failure, and infections returning over 6 months. Follow-up visits may occur during hospital admission or at home, and safety and treatment outcomes will be carefully tracked throughout the study period.